1-4 of 4
Justin Earp
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Deepti Telaraja, Yvette L. Kasamon, Justin S. Collazo, Ruby Leong, Kun Wang, Ping Li, Elyes Dahmane, Yuching Yang, Justin Earp, Manuela Grimstein, Lisa R. Rodriguez, Marc R. Theoret, Nicole J. Gormley
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 17–22.
https://doi.org/10.1158/1078-0432.CCR-23-1272
Published: 05 January 2024
View article titled, FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Open the PDF for FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma in another window
Journal Articles

FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes

Nina Kim, Kelly J. Norsworthy, Sriram Subramaniam, Haiyan Chen, Michael L. Manning, Eliford Kitabi, Justin Earp, Lori A. Ehrlich, Olanrewaju O. Okusanya, Jonathon Vallejo, Brenda J. Gehrke, R. Angelo de Claro, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3411–3416.
https://doi.org/10.1158/1078-0432.CCR-21-4498
Published: 15 August 2022
View article titled, FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes
Open the PDF for FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes in another window
Includes: Supplementary data
Journal Articles

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

Geoffrey Kim, Amy E. McKee, Yang-Min Ning, Maitreyee Hazarika, Marc Theoret, John R. Johnson, Qiang Casey Xu, Shenghui Tang, Rajeshwari Sridhara, Xiaoping Jiang, Kun He, Donna Roscoe, W. David McGuinn, Whitney S. Helms, Anne Marie Russell, Sarah Pope Miksinski, Jeanne Fourie Zirkelbach, Justin Earp, Qi Liu, Amna Ibrahim, Robert Justice, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (19): 4994–5000.
https://doi.org/10.1158/1078-0432.CCR-14-0776
Published: 30 September 2014
View article titled, FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAF<sup>V600E</sup> Mutation
Open the PDF for FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAF<sup>V600E</sup> Mutation in another window
Journal Articles

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne Pilaro, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (17): 4331–4338.
https://doi.org/10.1158/1078-0432.CCR-10-0570
Published: 31 August 2010
View article titled, U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Open the PDF for U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab in another window